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Abstract
Introduction There are limited data from randomized
controlled clinical trials on the outcomes of biologics after
discontinuation of a different systemic therapy. To deter-
mine the efficacy of adalimumab in patients who previ-
ously received systemic therapy (including failed therapy),
we performed a pooled post hoc analysis of Psoriasis Area
and Severity Index (PASI) response data from three dou-
ble-blind, placebo-controlled clinical trials in patients with
moderate to severe psoriasis.
Methods Patients from the M02-528, REVEAL, and
CHAMPION studies who were previously exposed to
systemic treatment were categorized based on their
response. The efficacy of adalimumab compared with
placebo was analyzed at the end of the double-blind
treatment period for the overall pooled intent-to-treat
population (N = 1469) and subgroups that received
(n = 780) or did not respond to (n = 229) previous sys-
temic pretreatments.
Results Rates for an improvement of C75 % from base-
line in the PASI score (PASI75 response) were signifi-
cantly greater (p\ 0.001) at week 16 in patients treated
with adalimumab compared with patients who received
placebo in the overall (72.1 vs. 8.0 %, respectively), pre-
viously treated (72.7 vs. 8.5 %), and previously failed
treatment (70.4 vs. 8.1 %) groups. PASI75 response rates
were similar in the overall group and in patients who did
not respond to methotrexate, cyclosporine, or psoralen plus
ultraviolet A therapy. Improvements of C90 or C100 %
from baseline PASI score were also higher with adali-
mumab vs. placebo in previously treated patients. Adverse
events were similar among subgroups.
Conclusions Adalimumab was efficacious for the treat-
ment of moderate to severe psoriasis regardless of prior
exposure to systemic therapies or failure of those prior
therapies.
ClinicalTrials.gov identifiers NCT00645814, NCT00237887,
NCT00235820.
Key Points
Patients with psoriasis treated with adalimumab
show significant improvement.
Patients with previous exposure to systemic therapies
demonstrated improvement comparable to those
without prior exposure to systemic therapies.
Patients who did not respond to systemic therapies
demonstrated improvement comparable to the
general psoriasis population.
1 Introduction
Current treatment guidelines suggest that psoriasis may be
treated with topical, ultraviolet (UV)-based, traditional
systemic, or biologic therapies, depending on specific
patient and disease characteristics [1–3]. The majority of
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patients with psoriasis who are prescribed biologic therapy
have previously received treatment with other systemic
therapies, including methotrexate (MTX), cyclosporine,
and psoralen plus UVA (PUVA) therapy. It is of clinical
relevance to understand whether patients who have
received prior systemic therapy, especially patients who
did not respond to previous treatment, will respond to
biologics to the same degree as patients who are naive to
systemic treatments.
Systemic therapies for the treatment of moderate to
severe psoriasis include MTX, which acts as an immuno-
suppressant and is often a first-line systemic therapy, and
cyclosporine, which is a short-term treatment alternative
owing to its potential for nephrotoxicity [4]. A third option is
PUVA, which uses naturally occurring, photosensitizing
psoralen compounds to sensitize cells to the effects of UVA
light and form psoralen-DNA crosslinks upon exposure,
thus preventing DNA replication [5]. Biologics approved for
the treatment of psoriasis have included agents that modu-
late T cells (e.g., alefacept and efalizumab [both withdrawn
from the market]) and inhibitors of tumor necrosis factor
(TNF; e.g., adalimumab, etanercept, and infliximab), inter-
leukin-12 and interleukin-23 (e.g., ustekinumab) [6–8], and
interleukin-17 (e.g., secukinumab) [9]. Apremilast is a
recently approved small-molecule inhibitor of phosphodi-
esterase 4 [10]. However, there are limited published clin-
ical trial data on the outcomes of systemic biologics after
discontinuing a different prior systemic therapy, particularly
following failure of the previous therapy.
The efficacy of adalimumab in the treatment of psoriasis
was demonstrated in two large, randomized, placebo-
controlled phase III trials. In the REVEAL trial, a signifi-
cantly greater percentage of patients receiving adalimumab
achieved an improvement of C75 % from baseline in the
Psoriasis Area and Severity Index score (PASI75 response)
compared with patients receiving placebo (71 vs. 7 %) [11].
In the CHAMPION trial, the superiority of adalimumab
over MTX and placebo was demonstrated by a significantly
greater percentage of patients receiving adalimumab
achieving PASI75 (79.6 %) compared with patients
receiving MTX (35.5 %) and placebo (18.9 %) [12].
The results of several small studies suggest that adali-
mumab may be an appropriate treatment option for patients
who have not achieved an adequate response to prior sys-
temic treatments, underscoring the need for confirmation
with additional data [13–18]. In this post hoc analysis, we
assessed the efficacy of adalimumab vs. placebo in patients
with psoriasis who received systemic therapy (biologics,
non-biologics, and/or oral PUVA) before enrolling in the
clinical trial, and included patients who experienced failure
(i.e., lack of improvement or worsening of psoriasis) with
one or more prior therapies.
2 Methods
2.1 Data Sources
Pooled data from three double-blind, placebo-controlled
efficacy and safety studies of adalimumab for the treatment
of moderate to severe psoriasis (N = 1469) were used for
this post hoc analysis. Patients from the placebo and
adalimumab (80 mg at week 0, then 40 mg every other
week [eow] starting at week 1) treatment groups were
included in the analysis. Patients who had received a sys-
temic biologic, non-biologic, or oral/topical PUVA were
identified; additionally, patients who had not responded to
prior treatments were also identified. Assessment of prior
treatment outcomes was based on patient self-report rather
than medical records or assessment scales. Prior treatment
was classified as treatment failure if the patient described
his or her psoriasis as the ‘‘same’’ or ‘‘worse’’ after the
treatment.
2.2 Study Design and Patients
The designs of the three studies used for this pooled post
hoc analysis have been described previously [11, 12, 19].
Study M02-528 [19] was a 12-week phase II study in which
148 patients were randomized in a 1:1:1 manner, with 147
patients receiving the following treatments: adalimumab
80 mg at week 0, followed by 40 mg eow starting at week
1 (n = 45); adalimumab 80 mg at weeks 0 and 1, followed
by 40 mg weekly starting at week 2 (n = 50); or placebo
(n = 52). PASI responses were evaluated at weeks 1, 2, 4,
8, and 12. The CHAMPION study [12] was a 16-week
phase III trial in which 271 patients were randomized in a
2:2:1 manner to receive adalimumab 80 mg at week 0,
followed by 40 mg eow starting at week 1 (n = 108);
MTX (not included in this analysis) 7.5–25.0 mg weekly
starting at week 0 (n = 110); or placebo (n = 53). PASI
responses were evaluated at weeks 1, 2, 4, 8, 12, and 16.
The REVEAL study [11] was a 16-week (Period A) phase
III trial in which 1212 patients were randomized in a 2:1
manner to receive adalimumab 80 mg at week 0, followed
by 40 mg eow starting at week 1 (n = 814) or placebo
(n = 398). PASI responses were evaluated at weeks 4, 8,
12, and 16.
Inclusion and exclusion criteria were similar for each
study, which facilitated combining data from the separate
study populations. Patients included adults with moderate
to severe plaque psoriasis that affected C10 % of body
surface area (C5 % for Study M02-528), who had a
Physician Global Assessment (PGA) of at least ‘‘moder-
ate’’ disease severity for the CHAMPION and REVEAL
studies, and a PASI score of C10 for the CHAMPION
80 K. A. Papp et al.
study or a PASI score C12 for the REVEAL study. Patients
who had previously used systemic TNF antagonists were
excluded from both studies; patients who had previously
used MTX were excluded from the CHAMPION study.
Washout periods for prior treatments were 2 weeks for
topicals and phototherapy, 4 weeks for non-biologic sys-
temic therapies (including PUVA in the REVEAL study),
6 weeks for efalizumab in the REVEAL study, and
12 weeks for biologic therapies.
2.3 Study Assessments
The primary efficacy endpoint was PASI75 response at
week 16 (except for Study M02-528, which was a 12-week
study). The PASI score (range 0–72) assesses the severity
of lesions with respect to erythema, induration, and
desquamation and the body surface area involved on the
head, torso, and upper and lower extremities. Improve-
ments of C90 and C100 % from baseline in PASI score
(PASI90 and PASI100, respectively) were similarly
assessed.
Information was collected on the prior use of systemic
treatments for psoriasis and patients’ self-reported recol-
lection of their response to treatment. For the M02-528
study, information about prior psoriasis treatments and
their effectiveness was collected for the previous
12 months; for the CHAMPION and REVEAL studies,
information about all lifetime psoriasis treatment was
collected, and response to treatments from the previous
12 months was recorded. Within each category of prior
treatment, multiple prior treatments per patient may have
been used. For this post hoc analysis, patients who recalled
that their psoriasis was the ‘‘same or worse’’ with a prior
therapy were considered to have had a lack of response.
2.4 Statistical Analyses
Efficacy data from the first 16 weeks (12 weeks for M02-
528) of the double-blind period of each study were pooled
and analyzed. Efficacy analyses were conducted using the
intent-to-treat population, and nonresponder imputation
was used for missing PASI data (i.e., patients with missing
PASI data were counted as nonresponders). The Fisher




Baseline demographics and clinical characteristics were
similar between treatment groups; the majority of patients
were male and white, and the mean disease duration was
18–19 years (Table 1). The clinical characteristics of the
treatment groups included in this analysis were typical of
patients with moderate to severe plaque psoriasis. Psoriasis
treatments received within the previous 12 months were
comparable between the placebo and adalimumab treat-
ment groups, with the majority of patients receiving
treatment with topical therapies (Table 2). The rates of
responses to prior therapies (i.e., failure [‘‘same or worse’’]
or improvement) were similar in the placebo and adali-
mumab groups in the trials analyzed here (Table 3).
3.2 Efficacy Assessments
Patients treated with adalimumab achieved significantly
higher PASI75 response rates compared with patients
receiving placebo, regardless of whether they had previ-
ously received systemic treatment or had not responded to
previous systemic therapy (Fig. 1). By 4 weeks (first
evaluation), PASI75 response rates were significantly
greater (p\ 0.001) in patients treated with adalimumab
compared with patients receiving placebo in all treatment
groups (overall, 19.4 % [187/966] vs. 1.4 % [7/503]; prior
treatment, 21.7 % [111/511] vs. 1.5 % [4/269]; and prior
failures, 15.6 % [25/160] vs. 0 % [0/69]; Fig. 1a). At
16 weeks, a significantly higher (p\ 0.001) percentage of




Placebo (n = 503) Adalimumab (n = 966)
Age, mean ± SD, years 45 ± 13 44 ± 13
Male, % 65 67
White, % 91 92
Body weight, mean ± SD, kg 93 ± 23 92 ± 23
Psoriasis duration, mean ± SD, years 19 ± 11 18 ± 12
BSA affected, mean ± SD, % 26 ± 15 27 ± 16
PASI score, mean ± SD 19 ± 7 19 ± 7
Psoriatic arthritis, % 28 27
BSA body surface area, PASI Psoriasis Area and Severity Index, SD standard deviation
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receiving placebo achieved PASI75 in all treatment groups
(overall, 72.1 % [664/921] vs. 8.0 % [36/451]; prior
treatment, 72.7 % [357/491] vs. 8.5 % [21/247]; and prior
failures, 70.4 % [107/152] vs. 8.1 % [5/62]; Fig. 1b).
Similar results between adalimumab and placebo were
observed for PASI90 and PASI100 responses. At 4 weeks,
PASI90 response rates were significantly greater
(p\ 0.001) in patients treated with adalimumab compared
with patients receiving placebo overall (4.6 % [44/966] vs.
0.2 % [1/503]) and in patients who had previously received
systemic therapy (4.3 % [22/511] vs. 0 % [0/269]);
improvement was not significantly different with adali-
mumab vs. placebo for patients who had not responded to
prior therapy (1.3 % [2/160] vs. 0 % [0/69]; Fig. 1a). No
statistically significant difference in PASI100 response
rates was observed between adalimumab and placebo at
4 weeks. At 16 weeks, however, significantly higher
(p\ 0.001) percentages of patients treated with adali-
mumab compared with placebo achieved PASI90 and
PASI100 in all groups based on prior treatment experience
(Fig. 1b).
For patients whose previous MTX therapy failed, the
percentage of patients achieving PASI75 at week 16 with
adalimumab was significantly greater than for patients who
received placebo (65.6 % [21/32] vs. 0 % [0/17];
p\ 0.001; Fig. 2). PASI90 rates were also higher with
adalimumab compared with placebo (46.9 % [15/32] vs.
0 % [0/17]; p = 0.001); however, PASI100 responses with
adalimumab compared with placebo (18.8 % [6/32] vs.
0 % [0/17]) were numerically greater but not statistically
significantly different. The sample sizes of patients with
failure of previous cyclosporine or PUVA therapy were
extremely small. At week 16, the percentage of patients
achieving PASI75 who did not respond to previous therapy
with cyclosporine or PUVA was numerically higher in
patients treated with adalimumab (71.4 % [5/7] and 83.3 %
[5/6], respectively) compared with patients receiving pla-
cebo (20.0 % [1/5] and 50.0 % [2/4], respectively; Fig. 2);
similar patterns were observed with PASI90 and PASI100
response rates.
3.3 Safety
Generally, adverse event (AE) occurrence was similar
across groups. Among the patients who reported AEs, most
reported typically mild to moderate AEs (Table 4). Serious
AEs occurred in B3 % of patients in any group; serious
infections occurred in B1 % of patients in any group. No
patients developed tuberculosis during the double-blind
randomized periods described in this analysis. One patient
receiving adalimumab and one receiving placebo had
malignancies other than lymphoma, hepatosplenic T-cell
Table 2 Psoriasis treatment
within the previous 12 months
Type of treatmenta, n (%) Placebo (n = 503) Adalimumab (n = 966)
Topical 380 (75.5) 743 (76.9)
Phototherapy 89 (17.7) 176 (18.2)
Systemic non-biologic 121 (24.1) 232 (24.0)
Acitretin 20 (4.0) 33 (3.4)
Tazarotene 17 (3.4) 17 (1.8)
Cyclosporine 18 (3.6) 32 (3.3)
Methotrexate 45 (8.9) 94 (9.7)
Other 31 (6.2) 76 (7.9)
Systemic biologic 63 (12.5) 106 (11.0)
Alefacept 23 (4.6) 34 (3.5)
Efalizumab 20 (4.0) 30 (3.1)
Other 24 (4.8) 43 (4.5)
Laser 3 (0.6) 4 (0.4)
a Patients may have received multiple previous treatments; therefore, the sums may exceed 100 %
Table 3 Response to prior psoriasis treatment within the previous 12 months
Prior treatment, n (%) Placebo group in current analysis Adalimumab group in current analysis
Prior response: same or worse Prior response: better Prior response: same or worse Prior response: better
Phototherapy 49 (55.1) 40 (44.9) 79 (44.9) 97 (55.1)
Systemic non-biologic 47 (38.8) 74 (61.2) 121 (50.0) 121 (50.0)
Systemic biologic 21 (31.8) 45 (68.2) 45 (41.7) 63 (58.3)
82 K. A. Papp et al.
lymphoma, leukemia, nonmelanoma skin cancer, or
melanoma.
4 Discussion
This analysis confirmed that adalimumab is efficacious for
the treatment of moderate to severe psoriasis in patients
who have received prior systemic therapy, including
patients who did not respond to previous treatment.
PASI75 response rates for patients treated with adali-
mumab who had previous exposure to, or lacked a response
to, other systemic therapies or phototherapy were similar to
the overall population. The effect was evident at the ear-
liest assessment (week 4) and was maintained through the
end of the analysis period (week 16). Similar patterns were
observed for PASI90 and PASI100 response rates. This
finding demonstrates that adalimumab is an efficacious
treatment option for patients who received prior systemic
therapy regardless of their prior treatment responses. There
were no unexpected differences in safety profiles between
adalimumab and placebo for the assessed groups that were
based on experience with prior psoriasis therapy.
Only a few small studies to date have examined the
effectiveness of adalimumab in patients who had an inad-
equate therapeutic response to other systemic therapies
[15–18]. Of these studies, two evaluated the efficacy of
adalimumab in patients who changed therapy from another
TNF antagonist [15, 16]. A third study included patients
who previously did not respond to conventional systemic
therapies and up to two TNF antagonists (etanercept and
infliximab) and, in some cases, also did not respond to
treatment with efalizumab [17]. A fourth study examined
patients who began treatment with adalimumab after fail-
ure of a variety of systemic therapies, including MTX,
cyclosporine, PUVA, retinoids, fumaric acid esters,
hydroxycarbamide, and biologics [18]. In an open-label
uncontrolled study in 50 patients whose prior etanercept
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b
Fig. 1 PASI75, PASI90, and PASI100 response rates overall and by
experience with prior systemic therapies at a 4 weeks and
b 16 weeks. Patients from Study M02-528 were excluded from the
analysis at 16 weeks because it was a 12-week study. PASI75,
PASI90, and PASI100 improvement of C75, C90, and 100 % from
baseline, respectively, in the Psoriasis Area and Severity Index score.












































































Fig. 2 PASI75, PASI90, and PASI100 response rates at week 16
overall and by type of prior failed systemic therapy. Patients from
Study M02-528 were excluded because it was a 12-week study. ADA
adalimumab, PASI75, PASI90, and PASI100 improvement of C75,
C90, and 100 % from baseline, respectively, in the Psoriasis Area and
Severity Index score, PBO placebo, PUVA psoralen plus ultraviolet
A. *p B 0.001 compared with placebo
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Table 4 Adverse events
Patients, n (%) Overall Prior exposure to systemic
therapies














AE 297 (59) 615 (64) 162 (60) 311 (65) 47 (68) 96 (60)
Serious AE 8 (2) 18 (2) 1 (\1) 10 (2) 0 4 (3)
AE leading to discontinuation 11 (2) 18 (2) 5 (2) 8 (2) 5 (7) 5 (3)
Severe AE 15 (3) 27 (3) 5 (2) 12 (2) 2 (3) 6 (4)
Drug-related AE 87 (17) 221 (23) 55 (20) 122 (24) 14 (20) 31 (19)
AE leading to death 0 0 0 0 0 0
Infection 118 (23) 287 (30) 63 (23) 154 (30) 20 (29) 42 (26)
Serious infection 4 (1) 5 (1) 0 3 (1) 0 1 (1)
Legionella infection 0 0 0 0 0 0
Diverticulitis 0 1 (\1) 0 0 0 0
Opportunistic infection
(excluding oral candidiasis and TB)
0 0 0 0 0 0
Oral candidiasis 0 0 0 0 0 0
TB 0 0 0 0 0 0
Parasitic infection 0 0 0 0 0 0
Reactivation of hepatitis B 0 0 0 0 0 0
PML 0 0 0 0 0 0
Malignancy 2 (\1) 6 (1) 0 2 (\1) 0 1 (1)
Lymphoma 0 0 0 0 0 0
HSTCL 0 0 0 0 0 0
NMSC 1 (\1) 4 (\1) 0 2 (\1) 0 1 (1)
Melanoma 0 1 (\1) 0 0 0 0
Leukemia 0 0 0 0 0 0
Malignancy other than lymphoma, HSTCL,
leukemia, NMSC, or melanoma
1 (\1) 1 (\1) 0 0 0 0
Allergic reaction (including angioedema and
anaphylaxis)
3 (1) 13 (1) 3 (1) 7 (1) 0 1 (1)
Lupus-like reactions and SLE 0 0 0 0 0 0
Vasculitis 0 0 0 0 0 0
Sarcoidosis 0 1 (\1) 0 1 (\1) 0 1 (1)
Autoimmune hepatitis 0 0 0 0 0 0
Myocardial infarction 1 (\1) 1 (\1) 1 (\1) 0 0 0
Cerebrovascular accident 0 0 0 0 0 0
CHF 0 1 (\1) 0 0 0 0
Pulmonary embolism 0 0 0 0 0 0
Interstitial lung disease 0 0 0 0 0 0
Intestinal perforation 0 0 0 0 0 0
Pancreatitis 0 2 (\1) 0 1 (\1) 0 0
Stevens–Johnson syndrome 0 0 0 0 0 0
Erythema multiforme 0 0 0 0 0 0
Psoriasis worsening or new onset 11 (2) 10 (1) 5 (2) 4 (1) 3 (4) 3 (2)
Demyelinating disorder 0 0 0 0 0 0
Amyotrophic lateral sclerosis 0 0 0 0 0 0
Reversible posterior leukoencephalopathy 0 0 0 0 0 0
Hematologic disorders (including pancytopenia) 1 (\1) 2 (\1) 1 (\1) 1 (\1) 1 (1) 0
Liver failure/event 2 (\1) 2 (\1) 0 1 (\1) 0 0
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therapy failed, 40 % achieved a PASI75 response at week
12 with adalimumab [16]. In an open-label retrospective
study in 13 patients treated with adalimumab after failure
of etanercept, PASI75 was achieved by two patients (15 %)
at week 12 and by three patients (23 %) at week 24 [15]. In
an open-label study of 30 patients whose psoriasis was
unresponsive to conventional systemic treatments and did
not respond to all other biologics, 87 % achieved a PASI75
response at week 12 with treatment with adalimumab [17].
In a retrospective study of 21 patients whose prior systemic
therapy failed, 38 % achieved a PASI75 response at week
16 with treatment with adalimumab [18]. These studies
were neither placebo controlled nor randomized; thus, the
results should be viewed with caution.
Two larger studies evaluated the efficacy of adalimumab
in patients who had previously not responded to other
systemic therapies that included biologics [13, 14]. In
patients who either never responded, lost response, or were
intolerant to prior TNF antagonist treatment (n = 282),
PASI75 response was achieved in 53.8, 65.7, and 50.0 % of
patients, respectively, following treatment with adali-
mumab for 16 weeks [13]. The current findings are con-
sistent with data from the PROGRESS trial, a 16-week,
open-label phase IIIb trial in which 61, 49, and 48 % of
patients (n = 152) with a suboptimal response to MTX,
etanercept, or phototherapy, respectively, achieved a PGA
of ‘‘clear’’ or ‘‘minimal’’ at week 16 of treatment with
adalimumab [14].
Although the current study included a large population
from placebo-controlled double-blind studies, the results
were obtained by a post hoc analysis of data pooled from
three different trials, with the resultant possibility of
heterogeneity; additionally, the statistical analyses were
not adjusted for multiple comparisons. Although no data
were collected after week 16, patients could continue
adalimumab for 252 weeks in an open-label extension
study (NCT00195676) [20]. Whereas response to adali-
mumab for this analysis was defined as PASI75, response
to prior therapy was based on patient recall, which may be
less reliable than data from medical records. It should be
kept in mind that the definition of treatment failure or
contraindication in clinical trials may not exactly corre-
spond to the definitions in clinical practice, which may be
influenced by the specific reimbursement system available
to the patient. Data were unavailable for prior reimburse-
ment status, the doses of prior therapies, and whether those
dosages were optimized. The analysis did not include
representative samples of patients who experienced treat-
ment failure with several therapies that are currently widely
used; for example, patients who received prior TNF
antagonists were excluded from the trials. The pre-speci-
fied washout periods did not reflect clinical practice, in
which patients may need treatment immediately following
failed therapies. For some prior treatment subgroups (i.e.,
cyclosporine and PUVA), the number of patients who
experienced treatment failure was small and may be
responsible for the lack of significance in these groups.
5 Conclusion
Adalimumab was efficacious for the treatment of moderate
to severe psoriasis regardless of prior exposure to or the
lack of a response to treatment with systemic therapies.
The PASI75, PASI90, and PASI100 responses for each
subgroup based on prior treatment were similar to those of
the overall population.
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